Novartis Analyst Price Targets - Benzinga

Novartis AG

NVSNYSE

Trade with Public

Trade with Public

$161.10

5.023.22%

마지막 업데이트: Oct 29, 6:54 PM

개요 뉴스 실적 전망 이벤트목표가재무 심리 지분 현황 배당금 비교 주식 보고서

© 2026 Benzinga | All Rights Reserved

Novartis Analyst Price Targets

Wall Street analyst price targets and consensus rating for Novartis (NVS).

Price Target Range — 7 Quarters

Analyst Consensus — 9 Analysts

2Buy

6Hold

1Sell

Consensus RatingNeutral# Analysts9Avg. Consensus PT$135Upside to Avg. PT-16.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 10, 2026	HSBC	Rajesh Kumar	Upgrade	Reduce→Hold	$123→$136
Mar 26, 2026	Morgan Stanley	Mark Purcell	PT Raise	Overweight	$143→$170
Jan 6, 2026	Barclays	Emmanuel Papada	Upgrade	Underweight→Equal-Weight	—
Dec 8, 2025	JP Morgan	Richard Vosser	Upgrade	Neutral→Overweight	—
Oct 27, 2025	Jefferies	Michael Leuchten	Assumes	Hold	—
Sep 12, 2025	Goldman Sachs	James Quigley	Downgrade	Neutral→Sell	$119→$118
Feb 13, 2025	UBS	Matthew Weston	Downgrade	Buy→Neutral	—
Nov 19, 2024	Erste Group	Hans Engel	Downgrade	Buy→Hold	—
Oct 30, 2024	BMO Capital	Etzer Darout	PT Raise	Market Perform	$118→$120
Sep 11, 2024	B of A Securities	Graham Perry	Downgrade	Buy→Neutral	$135→$130
Sep 5, 2024	Goldman Sachs	James Quigley	Downgrade	Buy→Neutral	$119→$121
Sep 3, 2024	Jefferies	Peter Welford	Downgrade	Buy→Hold	—
Jul 2, 2024	Jefferies	Peter Welford	PT Raise	Buy	$121→$123
Apr 24, 2024	BMO Capital	Etzer Darout	PT Raise	Market Perform	$114→$116
Feb 23, 2024	BMO Capital	Etzer Darout	Initiate	Market Perform	$114
Jan 23, 2024	Morgan Stanley	Mark Purcell	Initiate	Equal-Weight	$114

Analyst Ratings News

PRO
HSBC Upgrades Novartis to Hold, Raises Price Target to $136

HSBC analyst Rajesh Kumar upgrades Novartis (NYSE:NVS) from Reduce to Hold and raises the price target from $123 to $136.

Benzinga Newsdesk

The Multiple Sclerosis Drug Race Just Got Hotter After Novartis’ Phase 3 Win

Novartis stock spikes 5% on positive Phase 3 REMODEL trial results for relapsing MS drug remibrutinib with no liver safety signals.

Vandana Singh

Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.

Vandana Singh

PRO
Morgan Stanley Maintains Overweight on Novartis, Raises Price Target to $170

Morgan Stanley analyst Mark Purcell maintains Novartis (NYSE:NVS) with a Overweight and raises the price target from $143 to $170.

Benzinga Newsdesk

Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst

Merck to buy Terns for $6.7 billion as Keytruda patent risk nears, boosting leukemia pipeline; analysts see upside and possible rival bids.

Vandana Singh

Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case

Avalo Therapeutics completed Phase 2 enrollment for AVTX-009, with mid-2026 data ahead. Cantor sees major upside if results impress, but warns shares could plunge if the trial disappoints.

Vandana Singh